Related Experiment Video
Updated: May 11, 2026

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Recent advances in de novo CD5+ diffuse large B cell lymphoma
Preetesh Jain1, Luis E Fayad, Andreas Rosenwald
1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
American Journal of Hematology
|May 23, 2013
Summary
CD5 expressing Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive subtype. Patients often present with advanced disease and poor response to standard treatments, necessitating further research for improved outcomes.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Diffuse Large B-cell Lymphoma (DLBCL) comprises various molecular and immunohistochemical subtypes.
- CD5 expressing DLBCL (CD5+ DLBCL) is recognized as a distinct subtype with an aggressive clinical course.
- CD5+ DLBCL constitutes approximately 5-10% of all DLBCL cases, with limited prior research, predominantly from Japan.
Purpose of the Study:
- To review and synthesize current knowledge on CD5+ DLBCL.
- To identify common clinical and molecular features of CD5+ DLBCL.
- To highlight treatment challenges and outcomes associated with CD5+ DLBCL.
Main Methods:
- Literature review of articles indexed in PubMed.
- Inclusion of abstracts from major international conferences up to April 2013.
- Analysis of clinical characteristics, treatment responses, and molecular features of CD5+ DLBCL.
Main Results:
- CD5+ DLBCL patients are typically older, predominantly female, with elevated LDH, more extranodal involvement, poor performance status, and increased CNS involvement.
- These patients exhibit inferior response to rituximab-containing regimens compared to CD5- DLBCL.
- The majority of CD5+ DLBCL cases align with the activated B-cell (ABC) subtype of DLBCL.
Conclusions:
- CD5+ DLBCL is characterized by aggressive features and poor treatment outcomes.
- While molecular studies offer insights, the precise role of CD5 expression in chemoresistance and disease progression remains unclear.
- Further research is crucial to improve therapeutic strategies and outcomes for patients with CD5+ DLBCL.
Related Concept Videos
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...